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Umbilical cord blood (CB) cells from unrelated donors have been increasingly used an alternattive donor source for hematopoietic cell transt
plantation (HSCT).1 Compared to other sources of 
HSCT, unrelated cord blood transplantation (UCBT) 
is rapidly available and is presumed to have a low risk of 
transmission of viral infections and is associated with 
a lower risk of grafttversusthost diseases (GVHD).1,2 
Because CB Ttcells are immunologically naïve, immune 
recovery remains delayed and insufficient and in fact 
some studies have shown that infectiontrelated mort
bidity remains a leading cause of mortality following 
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BACKGROUND AND OBJECTIVES: stem cells from umbilical cord blood (CB) have increasingly become a vi-
able alternate source of progenitor cells for hematopoietic cell transplantation (hsCt). Cytomegalovirus (CmV) 
is thought to contribute significantly to hsCt morbidity and mortality. 
DESIGN AND SETTING: retrospective case-control study in patients at tertiary care center.
PATIENTS AND METHODS: We determined the incidence, risk factors and outcomes for CmV infection and 
disease after unrelated cord blood transplantation (uCBt) in children.
RESULTS: Between 2003 and 2007, 73 pediatric patients underwent uCBt and 68% of recipients were CmV 
seropositive. the overall incidence of CmV infection, early and late CmV infection was 58.9% (43/73), 62.8% 
(27/43), and 37.4% (16/43), respectively. in patients with early CmV infection, 6 of 27 (22%) patients progressed 
to develop CmV end-organ disease including pneumonitis and retinitis. high levels CmV antigenemia ≥70 in-
fected cells by pp65 antigenemia assay + Pmns, P=.237) were associated with a higher risk of progression to 
CmV disease. the development of CmV infections was higher in CmV-seropositive recipients (P<.001) and in 
those who developed graft-versus-host-diseases (GVhD) (P<.001). other risk factors for CmV infection include 
the use of high-dose corticosteroids (P<.001) and older age of the recipient at the time of transplant (P<.002). 
Late CmV infection was strongly associated with a previous history of early CmV infection (P<.001).
CONCLUSION: CmV infection is a significant complication in uCBt recipients in pediatric patients and is 
associated with an increase in transplant-related morbidity and mortality. risk factors for CmV infections after 
uCBt include GVhD, use of corticosteroids, underlying diseases (hematologic malignancies) and older age. 
Late CmV infection was strongly associated with a previous history of CmV infection. 
unrelated UCBT.3,4 CMV infection still represents the 
most common viral infection leading to morbidity and 
mortality in patients undergoing HSCT. Risk factors 
for CMV reactivation include: prior CMV infection 
in the donor or recipient, the use of hightdose corticot
steroids, Ttcell depletion, acute and chronic GVHD 
and age.5t8 CMV reactivation and infection will occur 
in 80% of patients who were CMV seropositive prior 
to HSCT and in 40% of seronegative patients, either 
because of the use of unscreened blood products, or set
ropositive stem cells. In the absence of antiviral prophyt
laxis, the risk of CMV disease was approximately 20% 
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to 35% among seropositive HSCT recipients.9 Unlike 
other sources of HSCT, CMV reactivation in UCBT 
is almost exclusively because of reactivation of the ent
dogenous virus in the host.10 This is because congenital 
CMV infection and infected UCB units are not genert
ally banked or used clinically. In this study, we report 
the incidence, risk factors of CMV reactivation and its 
impact on UCBTtassociated outcomes.
PATIENTS AND METHODS
The study included pediatric patients that underwent 
UCBT at King Faisal Specialist Hospital and Research 
Centre in Riyadh (KFSHRC), Saudi Arabia between 
January 2003 and December 2007. The hospital etht
ics committee approved this study. No problems were 
encountered in the shipment of the cord blood units 
from the international banks. Unrelated CB was obt
tained from the New York Blood Center (NYBC) and 
the National Cord Blood Program (NCBP) in Saudi 
Arabia, which was established in 2008. 
The conditioning regimens were tailored according 
to the underlying disease with antithymocyte globut
lin (ATG) included in the conditioning regimens of 
61 patients. A total of six patients with primary imt
munodeficiency disorders received reducedtintensity 
conditioning (RIC) because they were deemed unfit 
to receive myeloablative conditioning (one patient had 
WiskotttAldrich disease, three patients had Omen synt
drome and two patients had severe combined immunot
deficiency syndrome and all had cotmorbid conditions). 
The RIC regimen consisted of intravenous melphalan 
140 mg/m2 times one dose, intravenous fludarabine 30 
mg/m2/dose times 5 doses and intravenous rabbit ATG 
(Fresenius, Bad Homburg, Germany) 10 mg/kg/dose 
times 4 doses. The median CD34 cell dose was 1.7×105 
kg. All patients received fluconazole and acyclovir for 
GVHD prophylaxis. All patients received cyclosporine 
and a short course of prednisone and granulocytetcolt
ony stimulating factor (GtCSF) from day+1 until neut
trophil engraftment. Engraftment was defined as white 
cell counts >1.0×109/L or absolute neutrophils counts 
>0.5×109/L for 2 consecutive days.
Prior to transplant, all patients were assessed for 
CMV exposure by serology using enzyme immunot
assay. Patients with CMV IgG antibody level >10.0 
Eμ/mL were considered positive. After transplant, all 
patients underwent weekly screening for CMV reactit
vation by either pp65 antigenemia (prior to 2006) or 
both pp65 antigenemia and  PCR CMV DNA (after 
2006) until day +100. Post UCBT after day+100, furt
ther CMV screening was based on clinical judgment. 
CMV infections were defined as either CMV antigent
emia (≥5 cells/slide) or CMV DNAemia as one or 
more CMVtDNA detected in plasma by PCR. Early 
CMV infection was defined as CMV pp65 antigenemia 
or positive CMV DNAemia occurring before day 100 
in UCBT, late CMV infections thereafter.
In case of CMV reactivation, patients received pret
emptive treatment with intravenous ganciclovir (induct
tion 5 mg/kg, twice daily). Foscarnet 60 mg/kg intrat
venously every 8 hours daily was used in patients with 
severe neutropenia. This protocol was continued until 
two negative CMVtantigenemia or CMVtPCR results 
were obtained. A maintenance dosage of ganciclovir: 
5 mg/kg/day as a single daily dose for 14t21 day was 
commenced thereafter. GtCSF was given to maintain a 
neutrophil count above 1.2×109/L. Secondtline treatt
ment with intravenous foscarnet was generally started 
if CMV antigenemia or DNAemia continued, not ret
sponding to the initial protocol within 2 weeks. CMV 
disease was defined as detection of virus in endtorgan 
tissue including the lung (bronchoalveolar lavage [BAL] 
sample) or gastrointestinal (GI) tract (histopathologic 
changes consistent with CMV).
This was a retrospective casetcontrol study. The 
cases include all patients classified as CMV positive 
whereas the controls were CMVtnegative patients. For 
assessment of risk factors for CMV infection posttranst
plantation, characteristics of case patients and control 
subjects were examined using the chitsquare test for catt
egorical variables and the twottailed test for continuous 
variables. Also, univariate odds ratios (OR) and 95% 
confidence intervals (CIs) were calculated. Multiple 
logistic regression was used to assess whether putative 
risk factors that were independently associated with 
CMV infection. All data was analyzed using SAS 9.1.3 
statistical software (SAS Institute, Inc. Cary, NC).
RESULTS
Between January 2003 to December 2007, 73 patients 
underwent UCBT at KFSHRC. Engraftment occurred 
in 93% of patients. The characteristics of the patient are 
provided in Table 1. Fifty (68%) were CMVtseroposit
tive and 23 (32%) seronegative. The patients were dit
vided according to their underlying disease into those 
with malignant (hematological malignancies) and nont
malignant disorders (Table 2). The overall incidence of 
CMV infections was 58.9% (43/73). Early infection 
occurred in 62.8% (27/43) at a median of 27 days after 
UCBT while late CMV infection occurred in 37.2% 
(16/43) with a median time of onset at day +102. 
CMV infection was detected in 33 patients by CMV 
antigenemia assay between 2003 and 2006 and by both 
CMV antigenemia and DNAemia in 10 patients bet
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tween 2006 and 2007. All the 10 patients gave positive 
results of DNAemia by PCR and had a median of 12 
days (range 6 to 20 days) before results were obtained 
by the antigenemia assay.
Several risk factors were identified for the occurrence 
of early CMV infection (Table 3). CMV infection oct
curred in a significantly higher proportion (42/50 
[84%]) of patients with positive CMV serology than 
among patient with negative serology (1/23[4.3%], 
P<.001). There was a significant reactivation of CMV 
infection in patients who received methylprednisolone 
and had GVHD (22/43 [51.2%]) versus (1/30 [3.3%], 
P<.001). Among CMV seropositive recipients the 
frequency of CMV infection was significantly higher 
among patients with underlying diagnosis of hematot
logical malignancies than among patients with nontmat
lignant diseases (21/43 [49%]) versus (4/30 [13.3%], 
P<.002). Logistic regression analysis showed that those 
risk factors were independently associated with a risk 
of CMV infection. Gender was not a risk factor for 
CMV infection: female (17/43 [39.5%]); male (12/30 
[40%], P<.968). However, an association was noticed 
with older age at transplant (mean [SD] 4.8 years [3.3] 
versus 2.3 years [29], P<.001.) 
All patients with late CMV infection had usually 
had prior CMV infection (15/15 [100%], P<.001). Six 
of twentytseven (22%) patients with early CMV infect
tion progressed to develop CMV endtorgantdiseases 
including pneumonia and retinitis. Disease progression 
was associated with high CMV antigemia (>70 int
fected cells pp65, P=.24) (Figure 1). Six patients develt
oped CMV pneumonia; two also had retinitis. In 4/6 
patients with pneumonia, diagnosis was confirmed by 
histopathology and, or intsitu hybridization. Two pat
tients with interstitial pneumonitis were CMVtculture 
positive in bronchoalveolar lavage (BAL) in the absence 
of other pathogens. Two patients died due to multiple 
organ failure, one patient had a CMV resistant strain 
isolated with mutation in the UL54 gene while receivt
ing high dose ganciclovir, and he died despite treatment 
with foscarnet and ganciclovir combinations.
DISCUSSION
The incidence and outcomes of CMV infections after 
UCBT have not been extensively described in pediatt
ric patients. Our study has shown a high incidence of 
active CMV infection during the second posttUCBT 
month (32t60 days), which corresponds to data in the 
literature that reports that the highest incidence of 
CMV infections occuring during the first 3 months 
post transplantation, secondary to a greater degree of 
immunosuppression.1,4 We found a significant correlat
Table 1. Patient characteristics.
Characteristic
Median age, years (range) 2.7 (0.3 – 11.5)
Gender (number of patients)
    Male 43
   Female 30
Ethic background  
(number of patients)
   Saudi Arabs 65
   Non-Saudi Arabs 07
   Non-Arabs 01
CMV serology 
(number of patients)
   Positive 50
   Negative 23
Table 2. Diseases categories for transplant patients.
Categories Number of Patients
Malignant disorders (hematological 
malignancies) 25
    Acute lymphocytic leukemia 10
    Acute myeloid leukemia 11
    Non-Hodgkin lymphoma 02
    Biphenotypic leukemia 02
Non-malignant disorders 48
    Bone marrow failure 10
    Primary immunodeficiency disease 29
    Inherited metabolic disorders 09
Table 3. Risk factors for early CMV.
Risk factors








Mean age at transplant 
years (SD) 4.8 (3.27) 2.3 (2.9) <.001
Gender (male) 26 (60%) 18 (60%) <.968
CMV seropositive 42 (97.7%) 8 (28.6%) <.001
Use of steroids 22 (51.2%) 1 (3.3%) <.001
Graft-versus-host disease 22 (51.2%) 1 (3.3%) <.001
Hematologic malignancies 21 (49%) 4 (13.3%) <.002
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tients who receive steroids and have GVHD (51.2% 
vs. 3.3%, P<.001. This association has been reported 
by previous investigators.28,30 
Two unique findings in this study were the obsert
vation that CMV infection was significantly higher 
among patients with underlying diagnoses of hematot
logical malignancies than among patient with nonthet
matologic diseases (49% vs. 13.3%, P<.002). The risk 
of underlying disease and its treatment has not been 
specifically studied as a risk factor for development of 
CMV reactivation or disease after allogeneic or autolot
gous HCT. Disease stage at bone marrow transplant 
and prior use of chemotherapy may be a contributing 
factor to immune suppression in patients with hematot
logical malignancies. Another interesting finding is that 
of significant CMV infection correlation with older 
age at transplant (4.8 years [SD=3.27] versus 2.3 years 
[SD=2.9], P<.001).
Several challenges remain to optimize the managet
ment of CMV reactivation in pediatric UCBT recipit
ents. First, the preferred preemptive strategy that is apt
plicable to UCBT has not established. We have introt
duced preemptive therapy based on the results of CMV 
antigenemia in most patients in our hospital. Of the 27 
patients with early CMV antigenemia, 6 progressed 
from CMV antigenemia to disease despite preempt
tive therapy. CMV disease develops with ≥70 pp65+ 
PMNs (none of these patients had CMV PCR assay). 
All patients who progressed to disease were CMV set
ropositive. These observations suggest preemptive adt
ministration of antitCMV agents might be required. 
Alternatively universal prophylaxis of CMV might 
be worth investigating in CMV seropositive pediatric 
patients who received UCBT.31 Second, identification 
of a cutoff level for realttime PCR assay in recipients 
would be an important indication of time to initiate 
antitCMV treatment, which would reduce the number 
of patients treated with preemptive therapy who are not 
destined to develop CMV disease. Also, the duration 
of preemptive therapy might be shortened by realttime 
PCR more than CMV antigenemia because more rapid 
negative conversions of viral reactivation were detected 
using this assay in HSCT.19,32,33
Most of the patients with CMV disease had pneut
monitis and two had retinitis. CMV pneumonia manit
fests with fever, nonproductive cough, and hypoxia and 
interstitial infiltrates on radiography. All patients had 
CMV antigenemia. The diagnosis of CMV pneumot
nia was established by detection of CMV by shelltvial 
culture, histology and intsite hybridization in BAL 
specimen. CMV pneumonia was associated with mort
tality—about onetthird of our patients with documentt
Figure 1. CMV antigenemia assay and outcome (2003- 2006) 
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tion between CMV antigenemia and CMV DNAemia; 
however, there were samples that had negative or low 
antigenemia counts along with large numbers of CMV 
DNA copies in plasma. Others also reported such 
discrepancies when comparing the antigenemia assay 
results and DNAemia, obtained with realttime PCR 
assay. DNAemia has been shown to correlate with the 
actual viral replication rate more closely than antigent
emia. However, no threshold DNAemia levels for trigt
gering the initiation preemptively has been clinically 
validated in large studies. Our study demonstrates that 
CMV infection is a significant complication in the postt
UCBT setting. The incidence of CMV reactivation in 
this study was 58.9%. When compared CMVtseronegt
ative recipients, CMVtseropositive recipients had a sigt
nificantly higher risk for activation (84% versus 4.3%, 
P<.001). Our findings were similar to previous reports, 
which had found that CMV reactivation in posttUCBT 
varied between 21% and 100%.10,11 CMV reactivation 
after HSCT has ranged from 12.8% to 22% in a study 
group containing both CMVtseronegative and CMVt
seropositive donors and recipients and 52% to 69% in 
CMV–seropositive donors and recipients.16
To date, only 6 studies have focused on CMV react
tivation following UCBT.1,8,10,17t22 The largest of these 
studies included 322 patients (both children and 
adults) from the University of Minnesota. CMV react
tivation (antigenemia) occurred in 51% of patients at 
a median of +40 days. In contrast, we found a higher 
rate and an early incidence of CMV reactivation in 
seropositive recipients. The differences in preparat
tory regimens and patient characteristics between that 
study and ours may have affected the incidence, and 
time of CMV reactivation. The present study suggests 
that CMV infection is significantly reactivated in pat
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ed CMV pneumonia died. Results from large studies 
in HSCT reporting on patients treated before 1990, 
show an incidence of CMV pneumonia ranging from 
11% to 15% with case fatality ranging from 87% and 
93%.20,21,23,24 The incidence of CMV resistance after pet
diatric UCBT is unknown. Resistance mutations are lot
cated within the UL97 kinase and on DNA polymerase 
(UL54) viral genes. One of our patients with CMV 
pneumonia and retinitis had a resistant strain isolated 
with a mutation in the UL54 gene. Mutation in CMV 
DNA polymerase UL54 can lead to GCV resistance 
and many strains are associated with cross resistance to 
cidofovir and some UL54 mutations also show crosst
resistance to foscarnet. The combinations of ganciclovir 
with foscarnet have demonstrated additive or synergistic 
effects against both ganciclovirt and foscarnettresistant 
strains in vitro. Clinical studies involving bone marrow 
transplant recipients and HIVtinfected patients suggest 
that the combination of ganciclovir and foscarnet may 
produce clearing of CMV infections; unfortunately our 
patients died despite the combination therapy and a 
hightdose of CMV immunoglobulin.
An increased incidence of late CMV infection has 
been reported during the last decade since the introduct
tion of ganciclovir for pretemptive therapy or prophylaxt
is.20,26 The incidence of late CMV infection was reported 
in approximately 50% of patients after allogeneic HSCT. 
In our study, late CMV infection occurred in 37.2% 
with a median time of onset at day +102. We found that 
prior detection of CMV infection within 3 months after 
UCBT was a significant risk factor for late CMV infect
tion (P<.001). Boeckh et al have reported similar findt
ings in HSCT.27 The delay in immunologic reconstitut
tion probably represents the major cause of late CMV 
infection. The lack of CMV specific Ttcells in the infused 
CB units in addition to the immunological immaturity of 
CB lymphocytes may be associated with a delayed recovt
ery of CMVtspecific immunity after CBT.34
In conclusion, the present study demonstrates that 
CMV infection is a significant complication in UCBT 
recipients in pediatric patients. CMV seropositivity is 
associated with an increase transplanttrelated morbidt
ity and mortality. Risk factors for CMV infections aft
ter UCBT include GVHD, use of corticosteroids, unt
derlying diseases (hematologic malignancies) and older 
age. Late CMV infection was strongly associated with 
a previous history of CMV infection. Pediatric larget
scale controlled studies including risktbased diagnosis 
and management guidelines are required to identify 
the optimal approach and strategy for CMV disease 
prevention.
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